These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 24485094)

  • 21. A multicenter clinical evaluation of a new monophasic combination: Minulet (gestodene and ethinyl estradiol).
    de Andrade RP
    Int J Fertil; 1989 Sep; 34 Suppl():22-30. PubMed ID: 2576253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Side effects of third generation progestagens].
    Sitruk-ware R
    Contracept Fertil Sex (Paris); 1993 Apr; 21(4):295-300. PubMed ID: 12318229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
    Kuhnz W; Schütt B; Power J; Back DJ
    Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive.
    Bilotta P; Favilli S
    Arzneimittelforschung; 1988 Jul; 38(7):932-4. PubMed ID: 2974702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of cycle control and effect on well-being of monophasic gestodene-, triphasic gestodene- and monophasic desogestrel-containing oral contraceptives. Gestodene Study Group.
    Bruni V; Croxatto H; De La Cruz J; Dhont M; Durlot F; Fernandes MT; Andrade RP; Weisberg E; Rhoa M
    Gynecol Endocrinol; 2000 Apr; 14(2):90-8. PubMed ID: 10836195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative review of third-generation progestins.
    Kafrissen ME; Corson SL
    Int J Fertil; 1992; 37 Suppl 2():104-15. PubMed ID: 1354657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M
    Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene.
    Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P
    Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
    Bonnar J; Daly L; Carroll E
    Int J Fertil; 1987; 32 Suppl():21-8. PubMed ID: 2906344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined oral contraception with desogestrel/ethinyl estradiol: tolerability profile.
    Kaunitz AM
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1028-33. PubMed ID: 8447356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
    Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
    Dieben TO; van Beek A; Coelingh Bennink HJ
    Arzneimittelforschung; 1991 Sep; 41(9):996-8. PubMed ID: 1839126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene.
    Serfaty D; Vree ML
    Eur J Contracept Reprod Health Care; 1998 Dec; 3(4):179-89. PubMed ID: 10036600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical acceptability of monophasic gestodene.
    Düsterberg B; Brill K
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 2):1398-404. PubMed ID: 2220965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical experiences with a gestodene containing oral contraceptive (femoden)].
    Gimes G; Valent S
    Acta Pharm Hung; 1998 Sep; 68(5):289-93. PubMed ID: 9805815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.